Clinical Guidance: Drug Interactions with Hormonal ... · Drug Interactions with Hormonal...

Copyright ©Faculty of Sexual & Reproductive Healthcare 2017

1

Clinical Guidance: Drug Interactions with Hormonal Contraception

January 2017 | FSRH


2

Drug Interactions with Hormonal Contraception

Purpose and scope

This document provides a summary of guidance for healthcare

professionals on interactions between hormonal contraception and other

drugs. This guidance does not consider the effects of underlying medical

conditions on hormonal contraception. The recommendations can be used

to guide clinical practice but they are not intended to serve alone as a

standard of medical care or to replace clinical judgement in the

management of individual cases.

Background Serum levels of contraceptive hormones may be altered by concomitant

use of other drugs and hormonal contraceptives may themselves alter

serum levels of concomitant drugs. Therefore drug interactions should

always be considered when prescribing hormonal contraception and other

drugs to women; there could be a risk of contraceptive failure or other

adverse effects.

Contraceptive efficacy may be affected by both changes in

pharmacokinetics and pharmacodynamics of hormonal contraceptives.

Pharmacokinetic interactions occur when one drug alters the

absorption, distribution, metabolism or excretion of another, thereby

altering its serum concentration and its effects. Therefore, drugs that

reduce the absorption, metabolism or excretion of hormones may

affect their bioavailability and potentially affect contraceptive efficacy.

Pharmacodynamic interactions occur when one drug directly

influences the clinical actions of another by synergy or antagonism.

For example, progestogen-only contraception might reduce the

efficacy of ulipristal acetate emergency contraception (UPA-EC)

because of opposing action on progesterone receptors or vice versa.

Useful sources of information As new drugs are introduced and pharmacological knowledge expands,

information in this guidance document may become outdated. The Clinical

Effectiveness Unit (CEU) strongly recommends using the guidance in

conjunction with sources of information that are updated regularly including:

British National Formulary (BNF) (www.bnf.org)

Stockley’s Drug Interactions (www.medicinescomplete.com/mc/index.htm)

– this is the most relevant and accurate drug interaction resource for the

UK population. Many National Health Service (NHS) healthcare

professionals can get free access to Stockley’s using an OpenAthens login.

Electronic Medicine Compendium (www.medicines.org.uk/emc)

– for summary of product characteristics for most UK-licensed medicines.

Online HIV Drug Interaction Checker (www.hiv-druginteractions.org)

– highlights potential drug interactions between hormonal contraception

and antiretroviral drugs.

Online Medscape Drug Interaction Checker*

(http://reference.medscape.com/drug-interactionchecker)

Clinicians should note that when using any third-party resource, the

decision to follow the advice is the user’s and should be based on their

clinical judgement and the woman’s individual circumstances.

*Please note:

Caution must be exercised with the Medscape Drug Interaction Checker. It is based

primarily on drugs used in the USA and there are some inconsistencies in terms of drug

interactions with contraception hormones used in the UK such as desogestrel.

Some potential interactions highlighted by the Medscape Drug Interaction Checker may not

be clinically relevant. For example, in 2011 both CEU and BNF advice changed in line with

expert opinion to advise that combined hormonal contraception (CHC) users are not

required to use additional contraception when taking non-enzyme-inducing antibiotics.

The Medscape Drug Interaction Checker may highlight interactions with contraceptive

hormones of which the clinical significance is unknown. For example, drugs which inhibit

hepatic enzymes may increase serum levels of contraceptive hormones. This does not

affect contraceptive effectiveness and any potential effect on contraceptive side effects or

risk profile is unknown.

http://www.bnf.org/

http://www.medicinescomplete.com/mc/index.htm

http://www.medicines.org.uk/emc

http://www.hiv-druginteractions.org/

http://reference.medscape.com/drug-interactionchecker


3

Stages of metabolism Drug interactions/effects Types of drugs

Absorption May be affected by drugs that cause

vomiting or severe diarrhoea, chelating drugs and drugs that alter gastric pH or gut transit.

Metabolism – enzyme induction

Cytochrome P-450 is the most important family of enzymes in drug metabolism.

If cytochrome P-450 enzymes are induced, the metabolism of concomitant drugs may be increased, potentially reducing the clinical effect. Once started, these drugs may induce cytochrome P-450 enzymes within 2 days and the effects are generally maximal within 1 week. After cessation, enzymes generally return to their previous level of activity within 4 weeks.

If cytochrome P-450 enzymes are inhibited, the metabolism of concomitant drugs may be decreased, potentially leading to toxicity and increased side effects.

Metabolism – enterohepatic circulation The degree of reabsorption of EE via the

enterohepatic circulation may vary between individuals.

There have been theoretical concerns about the effect that this reabsorption of EE may have in terms of contraceptive efficacy but to date it is unproven.

There is no enterohepatic circulation of progestogens in their active forms and thus contraceptive efficacy is unaffected by changes in gut flora.

En

tero

he

pa

tic

cir

cu

lati

on

Absorption Drugs that increase gastric pH (including proton pump

inhibitors, antacids and H2-receptor antagonists) may reduce absorption and efficacy of ulipristal acetate (UPA).

Drugs that induce diarrhoea or vomiting. Metabolism Enzyme inducing drugs that may decrease contraceptive efficacy:

Antiepileptics (e.g. carbamazepine, eslicarbazepine, fosphenytoin, oxcarbazepine, phenobarbital, phenytoin, primidone, rufinamide, topiramate)

Antibacterials (e.g. rifabutin, rifampicin) Antiretrovirals (e.g. ritonavir, ritonavir-boosted protease

inhibitors, efavirenz, nevirapine) Antidepressants (e.g. St John’s wort – a herbal preparation) Others (e.g. modafinil, bosentan, aprepitant).

Enzyme inhibiting drugs that may increase hormone levels:

Antibacterials (e.g. erythromycin) Antifungals (e.g. fluconazole, itraconazole, ketoconazole,

posaconazole, voriconazole) Antiretrovirals (e.g. atazanavir) Immunosuppressants (e.g. tacrolimus) Non-sterodial anti-inflammatories (e.g. etoricoxib) Statins (e.g. atorvastatin, rosuvastatin) Vasodilators (e.g. sitaxentan sodium).

Drugs with unknown effects on enzymes Lamotrigine (antiepileptic) and griseofulvin (antifungal) are not thought to be enzyme-inducing drugs; however, contraceptive efficacy may be reduced by concurrent use. The clinical significance of this effect is unknown. It is unclear whether acitretin, etretinate and isotretinoin (retinoids) affect the reliability of oral progestogen-only contraception. However, they are not generally considered reliable enough for use with these teratogenic drugs. Combined oral contraceptives (COCs) are not affected by these drugs.

Excretion Active EE is excreted from urine. Conjugated metabolites that are not split in

the bowel are excreted in faeces.

Liver and intestinal mucosa Contains Phase I enzymes

(mixed-function oxidases) and Phase II enzymes, microsomal enzymes involved in the metabolism of contraceptive hormones and other drugs.

EE and progestogens are conjugated with glucuronic acid and sulphate to form glucuronides and sulphates.

Excreted into bile and into the small intestine.

Large intestine Hydrolytic enzymes from

colonic bacteria cleave conjugates of EE.

Active EE is reabsorbed from the large bowel via enterohepatic circulation.

Metabolism (first pass)

Absorption

Small intestine Oral ethinylestradiol (EE) and

progestogens are absorbed.

Drugs affecting the metabolism of hormonal contraception


4

Effects of contraceptive hormones on other drugs

The plasma concentration of some drugs can be altered by concurrent hormonal contraceptive use.

Women on drugs that are affected by contraceptive hormones may require monitoring of drug levels or drug effects when starting, changing or stopping

hormonal contraception. The woman’s specialist and/or general practitioner should be involved in decisions to change her contraception in these

situations.

Decreased levels or clinical effect Antiepileptics: Combined hormonal contraception (CHC)

moderately reduce lamotrigine exposure. This can lead to

decreased seizure control in the active hormone phase, and

then increased lamotrigine exposure with a risk of toxicity in

the hormone-free week. Desogestrel might increase

lamotrigine levels and adverse effects. EE may modestly

reduce sodium valproate levels.

Progestogen receptor modulators: Recent evidence

suggests that quick starting hormonal contraception after

ulipristal acetate (UPA) for emergency contraception (EC)

may reduce EC effectiveness. There is also a theoretical risk

that ulipristal acetate (e.g. EllaOne® for EC or Esmya® for

treatment of fibroids) may reduce efficacy of hormonal

contraception, although this has not been demonstrated to

date in clinical studies.

Possible adverse effects and/or consider some monitoring:

Antihypertensives: Estrogens may increase blood pressure

and antagonise antihypertensive efficacy.

Antidiabetics: Estrogens may antagonise the hypoglycaemic

effect of antidiabetics. The control of diabetes may be affected

in some women while taking hormonal contraceptives but it is

unusual for it to be seriously disturbed.

Anxiolytics and hypnotics: Estrogens and progestogens

may reduce plasma concentration of lorazepam, oxazepam

and temazepam.

Thyroid hormones: Estrogens may increase the requirements

for thyroid hormones in hypothyroidism.

Increased levels or adverse effect Immunosuppressants: EE might increase tacrolimus concentrations and levels can

be monitored by the woman’s specialist if required. Theoretically tacrolimus might also

increase hormonal contraceptive exposure. Ciclosporin levels may be increased by

estrogens and progestogens. UPA is predicted to increase everolimus and sirolimus

concentrations.

Dopaminergics: Selegiline levels potentially increased by estrogens and

progestogens. Increased risk of toxicity. Manufacturers advise concurrent use should be

avoided. EE reduces the clearance of ropinirole by about one-third.

Anxiolytics and hypnotics: Estrogen increases plasma concentrations of melatonin.

Possible adverse effects and/or consider some monitoring:

Antifungals: Estrogens and progestogens may increase levels of voriconazole.

Anxiolytics and hypnotics: Estrogens and progestogens may increase plasma

concentrations of chlordiazepoxide, diazepam and nitrazepam.

Bronchodilators: Estrogens slightly reduce the clearance of theophylline resulting in

increased plasma concentrations. Reducing dosage is recommended if adverse effects

occur.

Muscle relaxants: Estrogens and progestogens may increase tizanidine levels and its

adverse effects.

Potassium-sparing diuretics and aldosterone antagonists: Additive hyperkalaemia

or hypotension might occur with drospirenone and potassium-sparing diuretics.

Retinoids: The adverse effects of oral contraceptives on lipids may be additive with

those of isotretinoin. As retinoids are teratogenic, the benefits of COC use may

outweigh risk and lipids should be monitored routinely during retinoid treatment.

Triptans: COCs appear to slightly raise level of frovatriptan, naratriptan and

zolmitriptan, but this is not thought to be clinically significant. Please refer to UKMEC

as CHC is contraindicated in some women with a history of migraine.


5

Clinical assessment and key considerations

General points to remember Healthcare professionals advising on and prescribing hormonal

contraception should always ask women about their current and

previous drug use including prescription, over the counter, herbal,

recreational drugs and dietary supplements.

Recent reports suggest widespread use of modafinil (an

enzyme-inducing drug) as a ‘smart drug’ to enhance

cognitive function during exam periods. Women known to be

taking modafinil off-licence should be warned about the

potential impact on contraceptive efficacy and be counselled

regarding appropriate methods of contraception to use.

Women using or considering hormonal contraception should be

informed about the potential for interactions with other drugs and

the need to seek the advice of a healthcare professional before

starting any new drugs.

Women can be reassured that the contraceptive efficacy

of both intrauterine contraception (Cu-IUD and LNG-IUS)

and injectable contraception (DMPA) are not affected by

any drug interactions.

Quick starting may be appropriate – consult FSRH guideline

on quick starting contraception.

Women should be advised about the importance of correct

contraceptive practice during periods of illness.

According to recent evidence, most broad-spectrum

antibiotics are non-enzyme-inducing and do not require any

special precautions. No additional contraceptive precaution is

required unless the antibiotics (and/or illness) cause vomiting

or diarrhoea.

For women using enzyme-inducing drugs

Women starting enzyme-inducing drugs should be advised

of potential interaction with hormonal contraception and be

offered a reliable method unaffected by enzyme-inducers.

Women using enzyme-inducing drugs who require EC

should be advised of the potential interactions with oral

methods and offered a copper intrauterine device (Cu-IUD).

If a Cu-IUD is unacceptable or unsuitable, a double dose of

levonorgestrel EC (LNG-EC) can be used.

Short-term use of enzyme-inducing drugs (<2 months) can

be managed more flexibly than longer-term use. Continuing

the method with consistent and careful use of condoms may

be appropriate.

A note on women using teratogenic drugs

It is essential that women of reproductive age who

are taking known teratogenic drugs (e.g.

methotrexate, some antiepileptic drugs and retinoids)

or drugs with potential teratogenic effects should be

advised to use highly effective contraception both

during treatment and for the recommended

timeframe after discontinuation.

Detailed information regarding teratogenic drugs is

available from the UK Teratology Information Service

(UKTIS) website (www.uktis.org).

http://www.uktis.org/


6

Quick reference for enzyme-inducing drugs and contraception

Drug type CHC POP IMP DMPA LNG-IUS Cu-IUD (EC) LNG-EC UPA-EC

Enzyme-inducers (during use and for 4 weeks afterwards)

Examples:

Antiepileptics

carbamazepine, eslicarbazepine, oxcarbazepine, phenobarbital, phenytoin, primidone, rufinamide topiramate

Antibiotics rifabutin, rifampicin

Antiretrovirals ritonavir, ritonavir-boosted protease inhibitors, efavirenz, nevirapine

Always use the HIV Drug Interaction Checker (www.hiv-druginteractions.org) to identify potential interactions

Antidepressants St John’s wort

Others modafinil, bosentan, aprepitant

Known clinical interaction:

avoid use & advise alternative method Potential interaction:

caution required

No clinical interaction:

method suitable



caution required


method suitable

Contraceptive methods: CHC, combined hormonal contraception; Cu-IUD, copper intrauterine device; DMPA, progestogen-only injectable: depot medroxyprogesterone acetate; EC, emergency contraception; IMP, progestogen-only implant; LNG-IUS, levonorgestrel-releasing intrauterine system; POP, progestogen-only pill: UPA, ulipristal acetate. Norethisterone enanthate (NET-EN) is rarely used in UK practice but should be considered as for DMPA.



7

Quick reference for non-enzyme-inducing drugs and contraception

Drug type CHC POP IMP DMPA LNG-IUS Cu-IUD (EC) LNG-EC UPA-EC

Lamotrigine (antiepileptic; non-enzyme-inducer)

Griseofulvin (antifungal; non-enzyme-inducer)

Drugs that alter gastric pH (e.g. antacids, H2 antagonist, proton pump inhibitors)

Drugs that cause severe diarrhoea or vomiting (e.g. orlistat)

Progestogen receptor modulators (e.g. UPA)



caution required


method suitable



caution required


method suitable

Contraceptive methods: CHC, combined hormonal contraception; Cu-IUD, copper intrauterine device; DMPA, progestogen-only injectable: depot medroxyprogesterone acetate; EC, emergency contraception; IMP, progestogen-only implant; LNG-IUS, levonorgestrel-releasing intrauterine system; POP, progestogen-only pill: UPA, ulipristal acetate. Norethisterone enanthate (NET-EN) rarely used in UK practice but should be considered as for DMPA.


8

Use of contraceptive methods when woman is using an enzyme-inducer (and within 28 days of stopping treatment)

Examples:

Antiepileptics

carbamazepine, eslicarbazepine, oxcarbazepine, phenobarbital, phenytoin, primidone, rufinamide topiramate

Antibiotics rifabutin, rifampicin

Antiretrovirals ritonavir, ritonavir-boosted protease inhibitors, efavirenz, nevirapine

Always use the HIV Drug Interaction Checker (www.hiv-druginteractions.org) to identify potential interactions

Antidepressants St John’s wort

Others modafinil, bosentan, aprepitant

Women starting enzyme-inducing drugs should be advised of potential interaction with hormonal

contraception and be offered a reliable method unaffected by enzyme-inducers.

Women using enzyme-inducing drugs who require EC should be advised of the potential interactions

with oral methods and offered a Cu-IUD. If a Cu-IUD is unacceptable or unsuitable, a double dose of

LNG-EC may be used.

Short-term use of enzyme-inducing drugs (<2 months) can be managed more flexibly than longer-term

use. Continuing the method with consistent and careful use of condoms may be appropriate.

Method Clinical recommendation

CHC

Women taking rifampicin and rifabutin should always be advised to change to an

alternative method.

If a woman wishes choice with other enzyme-inducing drugs, consider use of a

minimum 50 μg (30 μg + 20 μg) EE monophasic pill during treatment and for a further

28 days with a continuous or tricycling regimen plus pill-free interval of 4 days.

Breakthrough bleeding may indicate low serum EE concentrations. Exclude other

causes (e.g. chlamydia) and dose of EE can exceptionally be increased up to a

maximum of 70 μg EE after specialist advice.

Use of two patches or two rings is not recommended.

POP

IMP

DMPA

LNG-IUS

Cu-IUD (EC)

LNG-EC

UPA-EC

• No interaction. • No need for extra precautions.

• Not advised. • Recommend an alternative method.



• Most effective method of EC.



• Can use DOUBLE DOSE i.e. 3 mg (2 x 1.5 mg tablet) as a single dose within <72 hours of unprotected sexual intercourse (UPSI) if Cu-IUD is declined or unsuitable.



9

Use of contraceptive methods when woman is using lamotrigine


CHC

POP

IMP

DMPA

LNG-IUS

Cu-IUD (EC)

LNG-EC

UPA-EC

Use of contraceptive methods when woman is using griseofulvin


CHC

If a woman wishes choice with griseofulvin, consider use of a minimum 50 μg (30 μg

+ 20 μg) EE monophasic pill during treatment and for a further 28 days with a

continuous or tricycling regimen plus pill-free interval of 4 days.

Breakthrough bleeding may indicate low serum EE concentrations. Exclude other

causes (e.g. chlamydia) and dose of EE can exceptionally be increased up to a

maximum of 70 μg EE after specialist advice.

Use of two patches or two rings is not recommended

As there is a theoretical risk of teratogenic effects with griseofulvin, use of

condoms during treatment and for 28 days after is also recommended.

POP

IMP

DMPA

LNG-IUS

Cu-IUD (EC)

LNG-EC

UPA-EC








• Can use DOUBLE DOSE i.e. 3 mg (2 x 1.5 mg tablet) as a single dose within <72 hours of UPSI if Cu-IUD is declined or unsuitable.





• May increase lamotrigine levels. Monitor for side effects. • No need for extra precaution.

Potential risk of reduced seizure control whilst taking CHC, and potential for

toxicity in the CHC-free week. The risks of using CHC may outweigh the

benefits and alternative methods should be considered.


10

Use of contraceptive methods when woman is using drugs that affect gastrointestinal function

Drugs altering gastric pH Examples: regular use of antacids, H2 antagonists and proton pump Inhibitors Drugs that increase gastric pH may reduce absorption and efficacy of UPA.


CHC

POP

IMP

DMPA

LNG-IUS

Cu-IUD (EC)

LNG-EC

UPA-EC

Drugs that cause severe diarrhoea or vomiting Examples: orlistat

Severe drug-induced diarrhoea or vomiting is predicted to reduce the bioavailability of contraceptive steroids.


CHC

POP

IMP

DMPA

LNG-IUS

Cu-IUD (EC)

EC-LNG

EC-UPA


• If vomiting occurs within <3 hours of taking pill or severe diarrhoea occurs for >24 hours, a repeat dose should be given. • If persistent diarrhoea or vomiting, consider Cu-IUD (EC). • Consistent use of condoms is recommended.







• Follow missed pill rules if vomiting occurs within <3 hours of taking pill or severe diarrhoea occurs for >24 hours. • If persistent diarrhoea or vomiting, consider non-oral method. • Consistent use of condoms is recommended.

• Effectiveness of UPA-EC may be reduced by drugs that raise gastric pH. • LNG-EC or Cu-IUD (EC) should be considered.


11

Use of contraceptive methods when woman is taking progesterone receptor modulators

Ulipristal acetate Quick starting hormonal contraception after UPA for emergency contraception may reduce EC effectiveness.

There is also a theoretical risk that UPA (e.g. EllaOne® for EC or Esmya® for treatment of fibroids) may reduce

efficacy of hormonal contraception, although this has not been demonstrated to date in clinical studies.


CHC

POP

IMP

DMPA

LNG-IUS

Cu-IUD (EC)

LNG-EC

UPA-EC

The CEU is grateful to the working group that developed this resource:

Dr Ailsa Gebbie Director, Clinical Effectiveness Unit and Consultant Gynaecologist

(Chalmers Centre, NHS Lothian)

Dr Zhong Eric Chen Researcher, Clinical Effectiveness Unit (Chalmers Centre, NHS Lothian)

Dr Michelle Cooper O&G Trainee and Research Fellow (Chalmers Centre, NHS Lothian)

Ms Jenny Greenfield Nurse Specialist in Contraception (Meridian Surgery, East Sussex)

Ms Claire Preston Lead Editor for Drug Interactions (Pharmaceutical Press)

Ms Shelley Raine Nurse Specialist in Contraception (Bournemouth)

Dr Carolyn Sadler General Practitioner (Brailsford & Hulland Medical Practice, NHS

Southern Derbyshire Clinical Commissioning Group)

The Clinical Effectiveness Unit (CEU) was formed to support the Clinical Effectiveness Committee of the Faculty of Sexual & Reproductive Healthcare (FSRH), the largest UK professional membership organisation working at the heart of sexual and reproductive healthcare (SRH). The CEU promotes evidence-based clinical practice and it is fully funded by the FSRH through membership fees. It is based in Edinburgh and it provides a member’s enquiry service, evidence-based guidance, new SRH product reviews and clinical audit/research. Find out more here.

Registered Charity No.1019969 | Registered in England No. 2804213 | VAT registration GB 628 1539 32

• Hormonal contraception should not be quick started until 5 days following UPA administration. • Consistent use of condoms is recommended.



• UPA-EC can be used more than once in the same cycle if further UPSI takes place.

• LNG-EC should not be used until 5 days after UPA administration.

https://www.fsrh.org/about-us/about-the-clinical-effectiveness-unit-ceu/


12

Clinical Guidance: Drug Interactions with Hormonal ... · Drug Interactions with Hormonal...

Documents

Transcript of Clinical Guidance: Drug Interactions with Hormonal ... · Drug Interactions with Hormonal...